The proinflammatory mediators leukotriene (LT) B 4 and LTC 4 must be transported out of cells before they can interact with LT receptors. Previously, we identified the multidrug resistance protein ABCC1 (MRP1) as an efflux pump for LTC 4 . However, the molecular basis for the efflux of LTB 4 was unknown. Here we demonstrate that human ABCC4 mediates the ATP-dependent efflux of LTB 4 in the presence of reduced glutathione (GSH), whereby the latter can be replaced by S-methyl GSH. Transport studies were performed with inside-out membrane vesicles from V79 fibroblasts and Sf9 insect cells that contained recombinant ABCC4, with vesicles from human platelets and myelomonocytic U937 cells, which were rich in endogenous ABCC4 whereas ABCC1 was below detectability. Moreover, human polymorphonuclear leukocytes contained ABCC4. K m values for LTB 4 were 5.2 µM with vesicles from fibroblasts and 5.6 µM with vesicles from platelets. ABCC4, with its broad substrate specificity, also functioned as an ATP-dependent efflux pump for LTC 4 with a K m of 0.13 µM in vesicles from fibroblasts and 0.32 µM in vesicles from platelets.
Introduction
Leukotrienes (LTs) are biologically potent proinflammatory lipid mediators mainly derived from arachidonate (for reviews see Samuelsson et al., 1987; Funk, 2001; Folco and Murphy, 2006) . The biosynthesis of LTB 4 and of LTC 4 is followed by a distinct export step recognized originally in human leukocytes (Lam et al., 1989; Lam et al., 1990) , murine mastocytoma cells (Schaub et al., 1991) , and plasma membrane vesicles from normal and transport-deficient rat hepatocytes (Keppler, 1992) . Efflux transport of LTB 4 and LTC 4 is an essential step in cells containing all enzymes of LT biosynthesis (for review see Funk, 2001) and also in transcellular LT biosynthesis (reviewed by Folco and Murphy, 2006) . Thus, LTA 4 taken up from other cells is actively converted to LTC 4 in platelets and effluxed by an energy-dependent export pump (Maclouf and Murphy, 1988; Sjölinder et al., 1999) .
Moreover, erythrocytes converted exogenous LTA 4 to LTB 4 which was subsequently exported into the extracellular space (Fitzpatrick et al., 1984) .
The multidrug resistance protein 1 (MRP1), now termed ATP-binding cassette transporter, subfamily C, member 1 (ABCC1) was the first ATP-dependent export pump identified for LTC 4 (Jedlitschky et al., 1994; Leier et al., 1994a) . The link between ABCC1 and LTC 4 as its substrate was established primarily by photoaffinity labeling studies using LTC 4 with its conjugated triene structure as a high-affinity ligand and the LTD 4 receptor antagonist MK571 as a competitive inhibitor of photoaffinity labeling and transport (Leier et al., 1994b; Jedlitschky et al., 1994; Leier et al., 1994a) . However, ABCC1 does not transport LTB 4 (see below). Thus, the molecular identity of the biologically important efflux transporter for LTB 4 has been unknown.
The members of the multidrug resistance protein subfamily, including ABCC1-6 and ABCC10-12, have a rather broad substrate specificity and mediate the ATP-dependent efflux of organic anions, including glutathione conjugates such as LTC 4 , across the plasma membrane into the extracellular space (for review see Deeley et al., 2006) . In the case of This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 24, 2007 as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from
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5 ABCC1 (Loe et al., 1996) and ABCC4 (MRP4; Rius et al., 2003; Rius et al., 2006) , it was recognized, however, that the presence or the co-transport of reduced glutathione (GSH) may change the substrate specificity and allow the efflux of substances that are not transported in the absence of GSH. GSH occurs in living cells at millimolar concentrations (Meister, 1988) , and modulation of the substrate specificity of ABCC transporters by GSH represents a physiological condition. For example, we showed that ABCC4 transports most bile acids only in the presence of GSH (Rius et al., 2003; Rius et al., 2006) .
These insights prompted us to study the ATP-dependent transport of LTB 4 and LTC 4 by ABCC4 in the presence or absence of GSH. ABCC4 is widely distributed in cells and tissues, including prostate (Lee et al., 2000) , urogenital tissues (Rius et al., 2005) , kidney proximal tubules (van Aubel et al., 2002) , astrocytes and capillary endothelial cells of the brain (Nies et al., 2004) , platelets (Jedlitschky et al., 2004) , erythrocytes (Klokouzas et al., 2003) , hepatocytes (Rius et al., 2003) , many cancer cells lines (Szakacs et al., 2004) , and, as shown in this contribution, in human neutrophilic polymorphonuclear leukocytes. Here we report our studies of the role of ABCC4 in the ATP-dependent efflux transport of LTB 4 and LTC 4 from cells. For this aim, we decided to use several cell lines stably expressing recombinant human ABCC4 (V79-ABCC4, HEK-ABCC4, and Sf9-ABCC4), as well as human platelets, HeLa, and U937 cells, which are remarkably rich in endogenous ABCC4.
This approach was taken because of the widespread occurrence of endogenous ABCC4/Abcc4 in cell lines used for transfection and because of the lack of human cell lines deficient in ABCC4. Otherwise, knock-out mice lacking Abcc4 expression, although a valuable animal model, do not provide a convincing answer to the question of the ATP-dependent transporter in the plasma membrane responsible for the release of LTB 4 because of major kinetic differences shown for other substrates between murine Abcc4 and human ABCC4 (Wolf de et al., 2007) and because of a likely compensatory adaptation by upregulation of alternative efflux pumps.
7 penicillin/streptomycin, and kept at 37 ºC and 5% CO 2 , as described (Rius et al., 2003) .
Human embryonic kidney HEK293 cells were grown in minimum essential medium (Sigma), supplemented with 10% (v/v) fetal bovine serum and 100 units/ml penicillin/streptomycin, and kept at 37 ºC and 5% CO 2 . HEK293 cells were transfected with the pREP9-ABCC4 cDNA construct or the vector only (Rius et al., 2003) , using FuGENE 6 transfection reagent (Roche Diagnostics, Mannheim, Germany). After 48 h, the cells were split, and stable transfectants were selected using medium with 1 mg/ml G418 (Gibco, Karlsruhe, Germany).
Resistant clones were screened by immunoblot analysis and immunofluorescence microscopy for ABCC4 expression as described (Rius et al., 2003) . Sodium butyrate (5 mM) was added to the cells 24 h before harvesting to enhance the expression of the recombinant protein (Cui et al., 1999) . The non-P-glycoprotein-expressing doxorubicin-resistant HL60-ADR cells (Marquardt et al., 1990; Krishnamachary and Center, 1993) were grown in RPMI medium (Sigma), supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin/streptomycin, and 200 nM daunorubicin, and kept at 37 ºC and 5% CO 2 (Jedlitschky et al., 1994) . The vector control transfected HeLa cells were grown in RPMI medium, supplemented with 10% (v/v) fetal bovine serum and 100 units/ml penicillin/streptomycin (Grant et al., 1994) . The parental U937 cells, a human myelomonocytic leukemia cell line, were obtained from the American Type Culture Collection (Manassas, VA) and were cultured in RPMI medium, supplemented with 10% (v/v) fetal bovine serum and 100 units/ml penicillin/streptomycin. Preparation of membrane vesicles from human platelets. Plasma membrane fractions from human platelets were isolated as described (Broekman, 1992; Jedlitschky et al., 2004) . Briefly, platelet-rich plasma was obtained from the Blood Center of the University of Heidelberg hospitals. The platelets were disrupted in homogenization buffer (100 mM KCl, 25 mM NaCl, 2 mM MgSO 4 , 12 mM Na 3 citrate, 10 mM D-glucose, 25 mM Hepes, 5
This article has not been copyedited and formatted. The final version may differ from this version. washed by centrifugation at 100,000 x g in incubation buffer (250 mM sucrose, 10 mM Tris/HCl, pH 7.4), and passed 20 times through a 27-gauge needle for vesicle formation.
Aliquots of the membrane vesicle suspension were stored in liquid nitrogen.
Preparation of membrane vesicles from human erythrocytes. Inside-out plasma membrane vesicles from human erythrocytes were prepared as described (Steck and Kant, 1974) . Briefly, human blood was obtained from a normal healthy donor and collected into EDTA syringes. Erythrocytes were washed three times by centrifugation at 2,300 x g for 10 min at 4 °C, discarding the buffy coat each time from the surface of the pellet. Hemolysis was achieved in 5P8 buffer (5 mM sodium phosphate, pH 8.0), followed by centrifugation at 25,000 x g for 10 min at 4 °C. The resulting membranous ghosts were suspended in 0.5P8 buffer (1:10 dilution of 5P8 buffer) and slowly mixed for 3 h on ice. After centrifugation at 25,000 x g (10 min at 4 °C), the membranes were washed by centrifugation at 40,000 x g (30 min at 4 °C) in 0.5P8 buffer. The membranes were resuspended in incubation buffer (250 mM sucrose, 10 mM Tris/HCl, pH 7.4) and passed 10 times through a 27-gauge needle for vesicle formation. Aliquots of the membrane vesicle suspension were frozen and stored in liquid nitrogen.
Preparation of membrane vesicles from mammalian cell lines. Inside-out plasma membrane vesicles from transfected V79 and HEK293 cells, HL60-ADR, control HeLa, and parental U937 cells were prepared as described (Keppler et al., 1998 
9 lysed by incubation in hypotonic buffer (0.1 mM EDTA, 0.5 mM sodium phosphate, pH 7.0) for 1.5 h, followed by homogenization with a Potter-Elvehjem homogenizer. After centrifugation of the homogenate at 12,000 x g (10 min at 4 °C), the postnuclear supernatant was centrifuged at 100,000 x g for 45 min at 4 °C. The resulting pellet was suspended in incubation buffer (250 mM sucrose, 10 mM Tris/HCl, pH 7.4), homogenized with a tight-fitting Dounce (glass/glass) homogenizer, and layered over 38 % sucrose in 5 mM HEPES/KOH, pH 7.4. After centrifugation at 280,000 x g for 1.5 h at 4 °C, the turbid layer at the interface was collected, washed by centrifugation in the incubation buffer (100,000 x g), and passed 20 times through a 27-gauge needle for vesicle formation. Aliquots of the membrane vesicle suspension were frozen and stored in liquid nitrogen.
Isolation of human PMNs. Human blood was obtained from a normal healthy donor and collected into EDTA-containing syringes. PMNs were isolated using a single-step gradient (Polymorphprep, Axis-Shield, Oslo, Norway) according to the manufacturer's instructions. Contaminating erythrocytes were lysed by hypotonic shock. The purity of PMNs was examined on Giemsa-stained smears indicating more than 97 % PMNs in the cell preparation.
Immunoblot analysis. Membrane vesicles (10-50 µg protein) from cell lines and human platelets and erythrocytes were diluted with sample buffer and incubated at 37 °C for 30 min before their separation on a 7.5 % SDS polyacrylamide gel. Immunoblotting was performed using a tank blotting system (Bio-Rad) and an enhanced chemiluminescence horseradish peroxidase detection system (Amersham Biosciences). The polyclonal SNG (Rius et al., 2003) 
10 studies, the SNG antiserum (1:1000 dilution) or the affinity-purified SNG antiserum (1:500 dilution) was incubated for 16 h at 4 °C with 10 µM of the synthetic peptide used to generate the SNG antiserum, and then applied onto the blots as the primary antibody. The horseradish peroxidase-conjugated goat anti-rabbit, anti-rat, and anti-mouse antibodies were used at dilutions of 1:2000, 1:5000, and 1:3000, respectively.
Confocal immunofluorescence microscopy of human PMNs and of cultured cells.
Isolated human PMNs and U937 cells were fixed for 30 min in 4 % paraformaldehyde, permeabilized for 30 min in 1 % Triton X-100 and immunostained as described (Rius et al., 2003) . The protein affinity-purified SNG antiserum was diluted 1:20 and the Alexa Fluor 488-conjugated goat anti-rabbit IgG was diluted 1:300. Confocal immunofluorescence pictures were taken on a LSM510 (Carl Zeiss, Oberkochen, Germany).
Vesicle transport studies. ATP-dependent transport of [
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11 of the solvent were used in control samples. NICK spin columns (0.2 g of Sephadex G-50 per 3.3 ml of incubation buffer) were prepared by rinsing with incubation buffer and were centrifuged at 400 x g for 3 min at 4 °C immediately before use. Aliquots ( Increasing amounts of membrane vesicles from human platelets were examined to compare the detection of ABCC4 and ABCC1 (Fig. 1B) . The SNG antiserum and the monoclonal antibody M 4 I-10 detected much greater signal intensity as the amount of protein increased (Fig. 1B , upper and middle panels), whereas the QCRL-1 antibody directed against ABCC1 detected no protein at all (Fig. 1B, lower panel) . A weak signal for ABCC1 was obtained only when the exposure time of the blot was extended 20 times as long as in Fig. 1B (data not shown). These results indicate that human platelets, HeLa-Control and U937 cells are a rich source of endogenous ABCC4 and have, if any, extremely low levels of endogenous ABCC1 ( Fig. 1A and B).
Cell lines expressing recombinant ABCC4 were also examined by immunoblotting (Fig. 1C) . The SNG antiserum detected a broad band at 170 to 190 kDa in membrane vesicles from hamster V79 fibroblasts and HEK293 cells transfected with recombinant ABCC4 (Fig.   1C ). The vesicles from the HEK293 cells transfected with the empty vector also showed a significant level of endogenous ABCC4 protein (Fig. 1C) . Vesicles from the Sf9 insect cells containing recombinant human ABCC4 presented a narrow band at 150 kDa, consistent with expression in a cell system which lacks complex glycosylation (van Aubel et al., 2002) .
Detection of ABCC4 in human PMNs and in parental U937 cells by confocal
laser scanning microscopy. Expression of ABCC4 was analyzed in human PMNs (Fig. 1D) and in U937 cells (Fig. 1D ) by immunofluorescence microscopy. Incubation of PMNs with the affinity-purified SNG antibody yielded strong fluorescent signals predominantly in intracellular membrane structures but also in the plasma membrane (Fig. 1D , upper panels).
This staining pattern was abolished in human PMNs (Fig. 1D , lower left panel), when the affinity-purified SNG antibody was preincubated with the synthetic SNG peptide. In the This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A and B) . The rates of ABCC4-mediated [ 3 H]LTB 4 transport increased 4.7-fold in the presence of 5 mM GSH (Fig. 2B) . A low rate of LTB 4 transport was detected in membrane vesicles from vector-transfected V79 cells (Fig.   2B ), which is in line with the presence of hamster Abcc4 in the V79 cells (Rius et al., 2003; Rius et al., 2006) . Similar results were obtained with the non-reducing GSH analog S-methyl GSH (data not shown). The LTB 4 transport in the presence of GSH was not significantly affected by DTT when present at a concentration of 1 mM.
Using membrane vesicles from the ABCC4-and vector-transfected HEK293 cells, the effects of GSH on the ATP-dependent transport of [ 3 H]LTB 4 were similar to those with the V79 cells ( Fig. 2C and D) . In the absence of GSH, LTB 4 transport was negligible (Fig. 2C) ;
however, addition of GSH caused an increase of the LTB 4 transport into membrane vesicles from both HEK-ABCC4 and HEK-Co cells (Fig. 2D ). The transport rates in the presence of GSH were proportional to the corresponding levels of recombinant and endogenous ABCC4 protein in HEK293 cells (Fig. 1C) . Membrane vesicles from Sf9 cells expressing recombinant ABCC4 confirmed the ABCC4-mediated LTB 4 transport in the presence of GSH (Fig. 3A ).
Thus, with three different cellular sources of recombinant ABCC4, ABCC4 was recognized as an ATP-dependent transporter of LTB 4 in the presence but not in the absence of GSH (Fig. 2 and Fig. 3A) . Similarly as shown earlier for the ABCC4-mediated cotransport of C-tau and GSH (Rius et al., 2003; Rius et al., 2006) , GSH could be replaced in the LTB 4 transport assays by S-methyl GSH (not shown). However, vesicles from U937, a myelomonocytic cell line, and HeLa control cells showed a pronounced and time-dependent ATP-dependent LTB 4 transport in the presence of GSH ( Fig. 3B and D) . These results indicate that LTB 4 transport in the presence of GSH by vesicles from human platelets, U937, and HeLa cells is mediated by endogenous ABCC4.
GSH increased ATP-dependent transport of LTB
ATP-dependent transport of LTC 4 and LTD 4 into membrane vesicles from V79, HEK293, and Sf9 cells, and from human platelets, U937, and HeLa cells. To further
characterize the substrate specificity of ABCC4 for leukotrienes, we measured transport of Fig. 4A and B) . Surprisingly, ATP-dependent LTC 4 accumulation at a concentration of 100 nM amounted to 32.3 ± 3.2 pmol x mg protein -1 after 5 min in vesicles from ABCC4-transfected V79 cells and to 14 ± 0.5 pmol x mg protein -1 in vesicles from vector-transfected V79 cells (Fig. 4A ). The accumulation of LTC 4 resulted in 2.2-fold higher transport rates in vesicles from V79-ABCC4 cells than in vesicles from V79-Co cells. This ABCC4-mediated transport was confirmed in vesicles containing recombinant ABCC4 from Sf9 cells (Fig. 4B) This article has not been copyedited and formatted. The final version may differ from this version. and from HEK293 cells. To further characterize the LTC 4 transport in membranes containing endogenous ABCC4, vesicles from human platelets were used (Fig. 4C) . These vesicles, which contained negligible levels of ABCC1 ( Fig. 1A and B) , mediated a significant transport of LTC 4 with a transport rate of 0.6 pmol x mg protein -1 x min -1 (Fig. 4C ).
Membrane vesicles from U937 and HeLa cells, which also showed very low levels of endogenous ABCC1 (Fig. 1A) , supported LTC 4 transport at a high rate (Fig. 4D ). Addition of GSH or S-methyl GSH did not further stimulate the transport of LTC 4 in vesicles containing recombinant or endogenous ABCC4 (data not shown).
ATP-dependent transport of [ 3 H]LTD 4 , which is structurally very close to LTC 4 , was also observed in vesicles from V79-ABCC4 cells with a rate of 1.0 pmol x mg protein -1 x min -1 in the absence of GSH (Fig. 5A) . Interestingly, the ABCC4-mediated transport of LTD 4 was stimulated by GSH with a rate of 3.1 pmol x mg protein -1 x min -1 in vesicles from V79-ABCC4 (Fig. 5B ). Membrane vesicles from platelets and U937 cells showed also LTD 4 transport with rates of 0.1 and 1.6 pmol x mg protein -1 x min -1 , respectively, and the addition of GSH also stimulated LTD 4 transport with rates of 0.2 and 2.5 pmol x mg protein -1 x min -1 , respectively.
Kinetic analysis of ABCC4-mediated ATP-dependent LTB 4 transport in the
presence of GSH and of ATP-dependent LTC 4 transport. To determine the K m value of ABCC4 for LTB 4 , we used vesicles containing recombinant ABCC4 from V79 cells and vesicles containing endogenous ABCC4 from human platelets (Table 1) . We tested the K m values using a concentration range from 0.1 to 1 µM LTB 4 in the presence of 5 mM GSH (Table 1 ). The V max values were 9.7 and 1.5 pmol x mg protein -1 x min -1 in vesicles from V79-ABCC4 and from platelets, respectively. The effect of GSH concentrations between 1 and 10 mM on the ATP-dependent [
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18 ABCC4 cells. At a constant concentration of 100 nM LTB 4 , the K m value of GSH for ABCC4 was 1.1 ± 0.2 mM.
The K m value of ABCC4 for LTC 4 was also determined in vesicles containing recombinant ABCC4 from V79 cells (Table 1) and vesicles containing endogenous ABCC4 from platelets (Table 1) (Table 2) . At a concentration of 1 µM, 5-and 12-hydroxyeicosatetraenoate did not cause a significant inhibition in the presence of GSH. In contrast, 1 µM LTC 4 was a potent inhibitor of the transport, causing 61 % inhibition, 1 µM LTD 4 caused 33 % inhibition, and the GSH derivative and LTC 4 analog, S-decyl glutathione at 10 µM caused 74 % inhibition. The non-steroidal anti-inflammatory drugs sulindac sulfide and indomethacin caused 74 % and 68 % inhibition, respectively, at 10 µM (Table 2 ). In the presence of GSH, the LTD 4 receptor antagonists MK571 and montelukast were also effective inhibitors of the LTB 4 transport. MK571 at 20 µM caused an inhibition of LTB 4 transport in the presence of GSH with a Ki value of 9.8 µM. In addition, several known ABCC4
substrates and ABCC inhibitors produced a significant inhibition (Table 2 ).
In vesicles from human platelets, LTC 4 transport was measured in the presence of several organic anions, especially LTD 4 receptor antagonists ( (Table 3) . Additional compounds were identified to show a GSH-dependent inhibition.
Accordingly, LTB 4 , LTD 4 , and C-tau caused inhibition only in the presence of GSH (Table 3 ). The presence of 5 mM GSH did not inhibit LTC 4 transport in the absence of inhibitors and the transport rates of LTC 4 were similar in the presence and absence of GSH.
This article has not been copyedited and formatted. The final version may differ from this version. (Figs. 1-5) . Moreover, millimolar concentrations of GSH were an absolute requirement for the ATP-dependent transport of LTB 4 (Figs. 2 and 3) , analogous to the ATP-dependent transport of most bile acids by ABCC4 (Rius et al., 2003; Rius et al., 2006) . In this study, we did not determine whether GSH is co-effluxed with LTB 4 , as is the case with cholyltaurine (Rius et al., 2003; Rius et al., 2006) or whether binding of GSH or S-methyl GSH to ABCC4 is sufficient. The LTB 4 efflux via ABCC4 in the presence of GSH is physiologically relevant, since millimolar concentrations (1 to 10 mM) of GSH occur in living cells (Meister, 1988) , including PMNs (Oliver et al., 1976) , erythrocytes (Kondo et al., 1980) , and platelets (Maclouf and Murphy, 1988) .
Our finding that LTC 4 is a full substrate for ABCC4 in the absence of GSH (Fig. 4 , Table 1 ) is consistent with the structural differences between the molecules: LTB 4 lacks the covalently bound GSH moiety of LTC 4 . The low K m value of the LTC 4 transport by ABCC4
( Fig. 4 and Table 1 ) contributes to an explanation of the active efflux transport of LTC 4 observed with blood platelets (Sjölinder et al., 1999) and erythrocyte membrane vesicles (Pulaski et al., 1996) . Both platelets and erythrocytes contain much ABCC4 and hardly any ABCC1 ( Fig. 1A and B) . The abundance of ABCC4 observed in the plasma membrane of these cells confirms recent studies from other laboratories (Klokouzas et al., 2003; Jedlitschky et al., 2004) . Our results suggest that all ATP-dependent LTC 4 efflux from platelets and erythrocytes is mediated by ABCC4. The high transport efficiency of ABCC4 in ATP-dependent LTC 4 export is indicated by the relatively high V max /K m ratio amounting to 30 in platelet vesicles and 288 in vesicles from V79-ABCC4 fibroblasts (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. (Maclouf and Murphy, 1988; Sjölinder et al., 1999; Folco and Murphy, 2006) . ABCC4 may thus play an important role in the transcellular synthesis of LTB 4 and LTC 4 . ABCC4 may be termed an eicosanoid efflux pump in view of its broad substrate spectrum that includes, in addition to LTB 4 and LTC 4 , prostaglandin (PG) E 2 (Reid et al., 2003) , PGF 2α , and thromboxane B 2 (Rius et al., 2005) .
In addition, ABCC4 expression was detected in human PMNs and in the human myelomonocytic leukaemia cell line U937 (Fig. 1D ). Confocal immunofluorescence microscopy indicated localization of ABCC4 in both cell lines in the plasma membrane and in intracellular vesicles. Further studies are required to determine whether the stimulation of PMNs and U937 with the calcium ionophore A23187 enhances the sorting of ABCC4 to the plasma membrane. The observation that membrane vesicles from U937 show ATP-dependent transport of LTB 4 in the presence of GSH (Fig. 3D) , of LTC 4 (Fig. 4D) , and of LTD 4
indicates that ABCC4 is at least partially localized to the plasma membrane and to plasma membrane derived vesicles. In this study we have not attempted to isolate inside-out membrane vesicles from human PMNs for additional experiments on LTB 4 transport.
Our work adds several inhibitors of ABCC4-mediated transport to those identified in recent years (van Aubel et al., 2002; Rius et al., 2003; Reid et al., 2003; Jedlitschky et al., 2004) . In this study, potent inhibitory compounds of ATP-dependent transport of LTB 4 in the presence of 5 mM GSH included LTC 4 and its structural analog S-decyl GSH, the antiinflammatory agent sulindac sulfide, and the LTD 4 receptor antagonists montelukast and MK571 ( Table 2 ). The latter substances also interfered with the ABCC4-mediated transport of LTC 4 in the absence of GSH (Table 3) . Some of these compounds were identified formerly as inhibitors of ABCC1, as described for MK571 (Jedlitschky et al., 1994; Leier et al., 1994a; Keppler et al., 1998) and S-decyl GSH (Loe et al., 1996) . Thus, the inhibitory selectivity of This article has not been copyedited and formatted. The final version may differ from this version. (Deeley et al., 2006) . Several of the inhibitors of LTB 4 transport by ABCC4 (Table 2) are established anti-inflammatory agents, such as indomethacin and sulindac sulfide. Inhibition of ABCC4 and thereby interference of the transcellular synthesis of LTB 4 and LTC 4 may contribute to the anti-inflammatory action of some anti-inflammatory drugs. However, anti-inflammatory agents must first be taken up by a target cell before they can interact with ABCC4 on its cytosolic domain, which was exposed in our inhibition studies with inside-out membrane vesicles. Moreover, the distribution and substrate specificity of the cellular uptake transporters and the site of drug administration in the body may determine whether an inhibitor of ABCC4 exerts anti-inflammatory actions.
Over the past years, ABCC4 has been recognized as a transporter of broad substrate specificity, including endogenous substrates, drugs, and drug candidates (Lee et al., 2000; van Aubel et al., 2002; Rius et al., 2003; Reid et al., 2003; Jedlitschky et al., 2004; Rius et al., 2005; Rius et al., 2006) . The physiological function of human ABCC4, however, cannot be 
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